Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo

Journal of Neurochemistry

Volumn 127, Issue 2, 2013, Pages 187-198

  Meyer, Andrew C ^a   Neugebauer, Nichole M ^b   Zheng, Guangrong ^c   Crooks, Peter A ^c   Dwoskin, Linda P ^d   Bardo, Michael T ^d  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

dopamine; GZ 793A; lobeline; methamphetamine; microdialysis; VMAT2

Indexed keywords

DOPAMINE; DRUGS USED IN THE TREATMENT OF ADDICTION; GZ 793A; LOBELINE; N (1 DIHYDROXYLPROPYL) 2,6 DI(4 METHOXYPHENETHYL)PIPERIDINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME MECHANISM; IN VIVO STUDY; MALE; MEDIAL PREFRONTAL CORTEX; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; ORBITAL CORTEX; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; REWARD;

DOPAMINE; GZ-793A; LOBELINE; METHAMPHETAMINE; MICRODIALYSIS; VMAT2;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DATA INTERPRETATION, STATISTICAL; DIHYDROXYPHENYLALANINE; DOPA DECARBOXYLASE; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; ELECTROCHEMISTRY; EXTRACELLULAR SPACE; LOBELINE; MALE; METHAMPHETAMINE; MICRODIALYSIS; NUCLEUS ACCUMBENS; RATS; RATS, SPRAGUE-DAWLEY; TYROSINE 3-MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

RATTUS;

EID: 84885428880     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12373     Document Type: Article

References (47)

1. Alvers K. M., Beckmann J. S., Zheng G., Crooks P. A., Dwoskin L. P., and, Bardo M. T., (2012) The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats. Psychopharmacology 224, 255-262.
2. Beckmann J. S., Denehy E. D., Zheng G., Crooks P. A., Dwoskin L. P., and, Bardo M. T., (2012) The effect of novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats. Psychopharmacology 220, 395-403.
3. Benwell M. E., and, Balfour D. J., (1998) The influence of lobeline on nucleus accumbens dopamine and locomotor responses to nicotine in nicotine-pretreated rats. Br. J. Pharmacol. 125, 1115-1119.
4. Besson M., David V., Baudonnat M., Cazala P., Guilloux J. P., Reperant C., Cloez-Tayarani I., Changeux J. P., Gardier A. M., and, Granon S., (2012) Alpha7-nicotinic receptors modulate nicotine-induced reinforcement and extracellular dopamine outflow in the mesolimbic system in mice. Psychopharmacology 220, 1-14.
5. Brown J. M., Hanson G. R., and, Fleckenstein A. E., (2000) Methamphetamine rapidly decreases vesicular dopamine uptake. J. Neurochem. 74, 2221-2223.
6. Brown J. M., Hanson G. R., and, Fleckenstein A. E., (2001) Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J. Pharmacol. Exp. Ther. 296, 762-767.
7. Champtiaux N., Gotti C., Cordero-Erausquin M., et al,. (2003) Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J. Neurosci. 23, 7820-7829.
8. Dani J. A., Jenson D., Broussard J. I., and, De Biasi M,. (2011) Neurophysiology of nicotine addiction. J. Addict. Res. Ther. S1, pii.
9. Davidson C., Lee T. H., and, Ellinwood E. H., (2005) Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences. Neurochem. Int. 46, 189-203.
10. Devoto P., Flore G., Saba P., Bini V., and, Gessa G. L,. (2013) The dopamine beta-hydroxylase inhibitor nepicastat increases dopamine release and potentiates psychostimulant-induced dopamine release in the prefrontal cortex. Addict. Biol. doi: 10.1111/adb. 12026 [Epub ahead of print].
11. Di Chiara G. D., (1995) The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend. 38, 95-137.
12. Dwoskin L. P., and, Crooks P. A., (2002) A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem. Pharmacol. 63, 89-98.
13. Eisenhofer G., Kopin I. J., and, Goldstein D. S., (2004) Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol. Rev. 56, 331-349.
14. Eyerman D. J., and, Yamamoto B. K., (2005) Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum. J. Pharmacol. Exp. Ther. 312, 160-169.
15. Fleckenstein A. E., Volz T. J., Riddle E. L., Gibb J. W., and, Hanson G. R., (2007) New insights into the mechanism of action of amphetamines. Annu. Rev. Pharmacol. Toxicol. 47, 681-698.
16. Garces-Ramirez L., Green J. L., Hiranita T., et al,. (2011) Sigma receptor agonists: receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis. Biol. Psychiatry 69, 208-217.
17. Gordon S. L., Quinsey N. S., Dunkley P. R., and, Dickson P. W., (2008) Tyrosine hydroxylase activity is regulated by two distinct dopamine-binding sites. J. Neurochem. 106, 1614-1623.
18. Guillot T. S., and, Miller G. W., (2009) Protective actions of vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol. Neurobiol. 30, 149-170.
19. Harrod S. B., Dwoskin L. P., Crooks P. A., Klebaur J. E., and, Bardo M. T., (2001) Lobeline attenuates d-methamphetamine self-administration in rats. J. Pharmacol. Exp. Ther. 298, 172-179.
20. Harrod S. B., Dwoskin L. P., Green T. A., Gehrke B. J., and, Bardo M. T., (2003) Lobeline does not serve as a reinforcer in rats. Psychopharmacology 165, 397-494.
21. Horton D. B., Siripurapu K. B., Zheng G., Crooks P. A., and, Dwoskin L. P., (2011) Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. J. Pharmacol. Exp. Ther. 339, 286-297.
22. Karobath M., (1971) Catecholamines and the hydroxylation of tyrosine in synaptosomes isolated from rat brain. Proc. Natl Acad. Sci. USA 68, 2370-2373.
23. Keath J. R., Iacoviello M. P., Barrett L. E., Mansvelder H. D., and, McGehee D. S., (2007) Differential modulation by nicotine of substantia nigra versus ventral tegmental area dopamine neurons. J. Neurophysiol. 98, 3388-3396.
24. Kumer S. C., and, Vrana K. E., (1996) Intricate regulation of tyrosine hydroxylase activity and gene expression. J. Neurochem. 67, 443-462.
25. Larsen K. E., Fon E. A., Hastings T. G., Edwards R. H., and, Sulzer D., (2002) Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J. Neurosci. 22, 8951-8960.
26. Mantle T. J., Tipton K. F., and, Garrett N. J., (1976) Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem. Pharmacol. 25, 2073-2077.
27. +) efflux from thalamic synaptosomes. Neuropharmacology 39, 2654-2662.
28. Miller D. K., Crooks P. A., Teng L., Witkin J. M., Munzar P., Goldberg S. R., Acri J. B., and, Dwoskin L. P., (2001) Lobeline inhibits the neurochemical and behavioral effects of amphetamine. J. Pharmacol. Exp. Ther. 296, 1023-1034.
29. Miller D. K., Lever J. R., Rodvelt K. R., Baskett J. A., Will M. J., and, Kracke G. R., (2007) Lobeline, a potential pharmacotherapy for drug addiction, binds to mu opioid receptors and diminishes the effects of opioid receptor agonists. Drug Alcohol Depend. 89 (2-3), 282-291.
30. Nakagawa T., Suzuki Y., Nagayasu K., Kitaichi M., Shirakawa H., and, Kaneko S., (2011) Repeated exposure to methamphetamine, cocaine or morphine induces augmentation of dopamine release in rat mesocorticolimbic slice co-cultures. PLoS ONE 6, e24865.
31. Narita M., Takagi M., Aoki K., Kuzumaki N., and, Suzuki T., (2003) Implication of Rho-associated kinase in the elevation of extracellular dopamine levels and its related behaviors induced by methamphetamine in rats. J. Neurochem. 86, 273-282.
32. Nickell J. R., Krishnamurthy S., Norrholm S., Deaciuc G., Siripurapu K. B., Zheng G., Crooks P. A., and, Dwoskin L. P., (2010) Lobeline inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2. J. Pharmacol. Exp. Ther. 332, 612-621.
33. Paxinos G., and, Watson C., (1998) The rat Brain in Stereotaxic Coordinates, 6th ed. Academic Press, London.
34. Rocha A., and, Kalivas P. W., (2010) Role of the prefrontal cortex and nucleus accumbens in reinstating methamphetamine seeking. Eur. J. Neurosci. 31, 903-909.
35. Rothman R. B., (1999) Is phentramine an inhibitor of monoamine oxidase? A critical appraisal. Synapse 32, 141-145.
36. Shimosato K., Nagao N., Watanabe S., and, Kitayama S., (2003) Suppressive effects of trihexyphenidyl on methamphetamine-induced dopamine release as measured by in vivo microdialysis. Synapse 49, 47-54.
37. Shoblock J. R., Sullivan E. B., Maisonneuve I. M., and, Glick S. D., (2003) Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats. Psychopharmacology 165, 359-369.
38. Sulzer D., Chen T. K., Lau Y. Y., Kristensen H., Rayport S., and, Ewing A., (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15, 4102-4108.
39. Sulzer D., Sonder M. S., Poulsen N. W., and, Galli A., (2005) Mechanism of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 75, 406-433.
40. Teng L., Crooks P. A., Sonsalla P. K., and, Dwoskin L. P., (1997) Lobeline and nicotine evoke [3H]overflow from rat striatal slices preloaded with [3H]dopamine: differential inhibition of synaptosomal and vesicular [3H]dopamine uptake. J. Pharmacol. Exp. Ther. 280, 1432-1444.
41. Teng L., Crooks P. A., and, Dwoskin L. P., (1998) Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine. J. Neurochem. 71, 258-265.
42. Vocci F. J., and, Appel N. M., (2007) Approaches to the development of medications for the treatment of methamphetamine dependence. Addiction 102 (Suppl 1), 96-106.
43. Vollm B. A., de Araujo I. E., Cowen P. J., Rolls E. T., Kringelbach M. L., Smith K. A., Jezzard P., Heal R. J., and, Matthews P. M., (2004) Methamphetamine activates reward circuitry in drug naïve human subjects. Neuropsychopharmacology 29, 1715-1722.
44. Wilhelm C. J., Johnson R. A., Eshleman A. J., and, Janowsky A., (2008) Lobeline effects on tonic and methamphetamine-induced dopamine release. Biochem. Pharmacol. 75, 1411-1415.
45. Zetterstrom T., Sharp T., Collin A. K., and, Ungerstedt U., (1988) In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC. Eur. J. Pharmacol. 148, 327-334.
46. Zheng G., Dwoskin L. P., Deaciuc A. G., Norrholm S. D., and, Crooks P. A., (2005) Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter. J. Med. Chem. 25, 5551-5560.
47. Zheng G., Dwoskin L. P., and, Crooks P. A., (2006) Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J. 8, E682-E692.